Biperiden for Prevention of Epilepsy in Patients With Traumatic Brain Injury
One of the most important neurological consequences following Traumatic Brain Injury (TBI) is the development of post traumatic epilepsy (PTE). Nevertheless, there is still no effective therapeutic intervention to reduce the occurrence of PTE. In previous studies with animals models of epilepsy, the biperiden decreased the incidence and intensity of spontaneous epileptic seizures besides delaying their appearance. The aim of this study is the evaluation of biperiden as antiepileptogenic drug to prevent PTE and also the determination of side effects, evaluating its cost-effectiveness in patients with moderate and severe TBI.
• Given informed consent
• 18 - 75 years of age
• GCS between 6 and 12 at hospital admission. GCS between 3 and 5 at hospital admission can be enrolled if patient was sedated at the accident scene with previous GCS between 6 and 15.
• Moderate or severe acute traumatic brain injury
• All genders
• Brain CT scan with signs of of acute intraparenchymal hemorrhage and/or contusion
• Able to receive the first dose of treatment or placebo within 18 hours of brain injury,